Tango Therapeutics (TNGX) TD Cowen 46th Annual Health Care Conference summary

Strategic vision and pipeline highlights

• Focus on advancing vopimetostat, a potent and selective PRMT5 inhibitor, with first and best-in-class potential for MTAP-deleted cancers, especially pancreatic and lung cancer.

• Strong financial position with $343 billion in cash, supporting accelerated clinical development and a cash runway into 2028.

• Emphasis on addressing high unmet medical needs and fast-to-market opportunities through innovative trial designs and regulatory engagement.

Clinical development and trial updates

• Launching a pivotal trial of vopimetostat monotherapy in second-line pancreatic cancer, with FDA support for trial design and endpoints.

• Ongoing proof-of-concept studies combining vopimetostat with RAS inhibitors (daraxonrasib, zoldonrasib) to position it as a foundational therapy for frontline pancreatic cancer.

• Expanding vopimetostat data in lung cancer and histology-selective cohorts, with updates expected later this year.

• TNG456, a CNS-penetrant PRMT5 inhibitor, is in early clinical trials for glioblastoma and non-small cell lung cancer, with updates anticipated.

Key clinical data and safety profile

• Vopimetostat shows a 27% objective response rate across tumor types and a benign safety profile, supporting its use in combination therapies.

• Median progression-free survival (PFS) of 7.2 months in pancreatic cancer and 9.1 months in histology-selective cancers, more than doubling standard of care outcomes.

• Combination trials with RAS inhibitors have reached clinically meaningful exposures with no adverse events reported so far.

• Only 8% dose reductions and no grade 4/5 related events observed in ongoing studies, highlighting strong tolerability.